COMP <GO>
NRXS vs MRK // RETURN ON INVESTED CAPITAL (ROIC)
Neuraxis Inc. (NYSE) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: NRXS 3
— MRK 8
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: MRK
LAST: $7.13 (-5.56%) • MKT CAP: $94.8M
roic
-35.00%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
roic
20.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NRXS VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NRXS | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 84.20% | 74.80% | +9.40 | NRXS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -35.00% | 20.70% | -55.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.82% | 3.42% | -10.24 | MRK | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.30% | -94.30 | MRK | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.10% | -88.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 32.90% | 1.30% | +31.60 | NRXS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.88 | 5.19 | -3.31 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.9 | 51.7 | +3.20 | NRXS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $94.8M | $361.02B | -$360.93B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NRXS REV | MRK REV | NRXS GROSS % | MRK GROSS % | NRXS FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.6M | $65.01B | 84.2% | 74.8% | -$6.5M | $12.36B |
| FY 2024 | $2.7M | $64.17B | 86.5% | 76.3% | -$6.1M | $18.10B |
| FY 2023 | $2.5M | $60.12B | — | — | -$6.7M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NRXS // BETA —
MRK // BETA 0.92